Motiva SmoothSilk硅胶乳房假体在初次与修正乳房增大患者中的安全性和有效性研究:三年临床数据
Motiva IDE是一项前瞻性、单臂、多中心、为期10年的关键性研究,提交给FDA的3年数据涵盖初次乳房增大(451例)和修正乳房增大(109例)队列,另有218例进入MRI队列。任何原因再手术率初次队列为6.1%(随访率92.4%),修正队列为25.8%(随访率88.7%)。3年数据表明Motiva假体安全有效,假体相关并发症率低,医生和患者满意度高。
要点
- 初次乳房增大队列451例,修正乳房增大队列109例,MRI队列218例。
- 任何原因再手术率:初次队列6.1%(随访率92.4%),修正队列25.8%(随访率88.7%)。
- 3年数据表明Motiva假体安全有效,假体相关并发症率低,医生和患者满意度高。
核心结论
- 提交给FDA的初次和修正乳房增大队列3年数据表明Motiva假体安全有效,假体相关并发症率低,医生和患者满意度高。
研究设计与样本
- Motiva IDE是一项前瞻性、单臂、多中心、为期10年的关键性研究,收集乳房增大、重建和修正手术数据。
- 提交给FDA的3年数据涵盖初次乳房增大队列451例和修正乳房增大队列109例,其中218例进入MRI队列。
- 部分患者在第1、2、3年接受年度磁共振成像(MRI)筛查假体破裂。
主要发现
- 任何原因再手术率初次乳房增大队列为6.1%(随访率92.4%),修正乳房增大队列为25.8%(随访率88.7%)。
- 3年Motiva数据提示,修正手术的主要原因已从包膜挛缩和破裂转向更为主观的再手术指征,如位置不良和尺寸改变。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Silicone breast implant design has evolved over the last 50 years. Regulatory bodies including the FDA require data to support the modifications designed to improve the safety, efficacy, longevity, and biocompatibility of breast implants. OBJECTIVES: The authors reviewed the 3-year data on the safety and effectiveness of Motiva (Establishment Labs Holdings, Inc., Alajuela, Costa Rica) SmoothSilk silicone gel-filled breast implants submitted to the FDA. The current submitted data include the primary breast augmentation and revisional augmentation cohorts. METHODS: The Motiva IDE is a prospective, single-arm, multicenter, 10-year pivotal study in which data are collected on breast augmentation, reconstruction, and revisional surgery. Three-year data were submitted to the FDA on adverse events, reoperations, patient and physician satisfaction, connective tissue diseases, and quality of life validated instruments. A subset of the patients underwent annual magnetic resonance imaging (MRI) at years 1, 2, and 3 to screen for implant rupture. RESULTS: A total of 451 patients were implanted in the primary augmentation cohort and 109 patients in the revisional augmentation cohort. There were 218 patients enrolled in the MRI cohort. Reported rates for reoperation for any reason were 6.1% in the primary augmentation cohort (92.4% follow-up) and 25.8% in the revisional augmentation cohort (88.7% follow-up). DISCUSSION: Motiva implants were first introduced in 2010. The 3-year Motiva data suggests that the leading cause of revisional surgery has shifted from capsular contracture and rupture to more subjective indications for reoperation such as malposition and size change. CONCLUSIONS: Three-year data from the primary augmentation and revisional augmentation cohorts submitted to the FDA demonstrate the safety and efficacy of the Motiva implants. There were low complication rates for implant-related complications and high surgeon and patient satisfaction.
引用
- Glicksman C, Wolfe A, McGuire P, et al. The Study of the Safety and Effectiveness of Motiva SmoothSilk Silicone Gel-Filled Breast Implants in Patients Undergoing Primary and Revisional Breast Augmentation: Three-Year Clinical Data. Aesthet Surg J. 2024. PMID: 39331509. doi:10.1093/asj/sjae134
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。